分子定义的成人型卵巢颗粒细胞瘤预测性生物标志物患病率
该回顾性横断面队列研究纳入423例FOXL2 c.C402G阳性的成人型卵巢颗粒细胞瘤肿瘤样本,评估FDA批准疗法相关预测性生物标志物。
要点
- 分子定义的aGCT中无MSI-H或高TMB,不符合帕博利珠单抗FDA批准条件。
- TP53突变亚群具有更高的TMB和gLOH评分。
核心结论
- 分子定义的aGCT中无患者基于MSI或高TMB符合FDA批准的帕博利珠单抗治疗条件。
- TP53突变识别出具有独特分子特征的一个亚群。
- 该罕见病的精准治疗选择仍是未被满足的关键需求。
研究设计与样本
- 回顾性横断面队列研究,纳入423例FOXL2 c.C402G阳性的分子定义aGCT肿瘤样本。
- 使用Foundation Medicine测序数据,涵盖最多406个基因的编码变异、微卫星不稳定、肿瘤突变负荷和基因组杂合性缺失。
- PD-L1表达采用DAKO 22C3免疫组化检测的肿瘤比例评分确定。
主要发现
- 样本提交时中位年龄57岁(四分位距48-65)。
- 平均肿瘤突变负荷为1.8个突变/兆碱基(范围0-8.8)。
- 无肿瘤表现为微卫星不稳定,也无gLOH-High(≥16%)。
- MTAP缺失12/173(5.8%),PIK3CA激活突变23/423(5.4%)。
关键数值与推荐
- gLOH-High定义为≥16%。
临床怎么用
- 对分子定义的aGCT,不应基于MSI或高TMB选择帕博利珠单抗治疗。
- 可考虑检测TP53突变以识别具有更高TMB和gLOH的分子亚群。
- MTAP缺失和PIK3CA激活突变可作为潜在可操作变异进行探索。
局限性
- 回顾性研究设计。
- MTAP缺失检测仅173例,数据不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to determine the prevalence of predictive biomarkers associated with FDA-approved therapies in molecularly defined adult-type ovarian granulosa cell tumors (aGCTs). METHODS: We performed a retrospective cross-sectional cohort study of tumor profiles using the inclusion criteria of molecularly defined (FOXL2 c.C402G positive) aGCTs previously sequenced at Foundation Medicine, Inc. The dataset included coding variants for up to 406 genes, microsatellite instability, tumor mutational burden, and genomic loss of heterozygosity (gLOH). PD-L1 expression was determined using the tumor proportion score, as measured using the DAKO 22C3 immunohistochemistry assay. RESULTS: 423 tumor profiles met inclusion criteria. The median age at the time of sample submission was 57 years (interquartile range 48-65). The mean tumor mutational burden was 1.8 mutations per megabase (range 0-8.8). No tumors exhibited microsatellite instability, and none were gLOH-High (≥16%). Sixty-seven tumors had PD-L1 expression measurement, and 94% were negative. Potentially actionable variants including MTAP deletion (12/173, 5.8%) and activating PIK3CA mutations (23/423, 5.4%) were identified. TP53-mutated aGCT had a higher tumor mutational burden (mean 2.4 mut/Mb, 95% CI 1.7-3.0 mut/Mb vs mean 1.7 mut/Mb, 95% CI 1.5-1.9 mut/Mb; P = .02) and higher gLOH score (mean 4.4%, 95% CI 2.7-6.1% vs mean 1.4%, 95% CI 1.2-1.6%; P = .002) than TP53 non-mutated tumors. CONCLUSIONS: No women with molecularly defined aGCT in this large cohort would be eligible for FDA-approved pembrolizumab based on either microsatellite instability or high tumor mutational burden. TP53 mutation identified a subset of this tumor type with distinct molecular features. The development of precision treatment options remains a critical unmet need for this rare disease.
引用
- Hillman RT, Lin DI, Lawson B, et al. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2021. PMID: 34238613. doi:10.1016/j.ygyno.2021.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。